The EGFR L858R variant leads to poor prognosis and high incidence of malignant pleural effusion in non-small cell lung cancer, and the current small molecule drugs are only moderately effective against this variant (Kohno et al., 2021; Matsui et al., 2021). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.